The molecular organization, toxicity studies, desired localization and biodistribution of cost effective AmB-SA-GCS-NP was found to be highly effective and can be proved as practical delivery platform for better management of leishmaniasis.

Sepsis is a clinical syndrome characterized by a multisystem response to a pathogenic assault due to underlying infection that involves a combination of interconnected biochemical, cellular and organ-organ interactive networks. After the withdrawal of recombinant human-activated protein C (rAPC), researchers and physicians have continued to search for new therapeutic approaches and targets against sepsis, effective in both hypo-and hyperinflammatory states. Currently, statins are being evaluated as a viable option in clinical trials. Many agents that have shown favourable results in experimental sepsis are not clinically effective or have not been clinically evaluated. Apart from developing new therapeutic molecules, there is great scope for for developing a variety of drug delivery strategies, such as nanoparticulate carriers and phospholipid-based systems. These nanoparticulate carriers neutralize intracorporeal LPS as well as deliver therapeutic agents to targeted tissues and subcellular locations. Here, we review and critically discuss the present status and new experimental and clinical approaches for therapeutic intervention in sepsis. AbbreviationsAKI, acute kidney injury; ANP, atrial natriuretic peptide; BNEP, bactericidal neutralizing endotoxin protein; BPI, bactericidal/permeability-increasing protein; C5aR, complement component 5a receptor; CLP, caecal ligation puncture; DHEA, dehydroepiandrosterone; GM-CSF, granulocyte macrophage colony-stimulating factor; GRK2, G protein-coupled receptor kinase 2; HDL, high-density lipoprotein; HLA-DR, MHC class II cell surface receptor encoded by the human leukocyte antigen; HMGB-1, high mobility group box-1; HMG-CoA, 3-hydroxy-3-methyl glutaryl coenzyme A; iNOS, inducible nitric oxide synthase; LBP, lipopolysaccharide binding protein;

No abstract

The findings suggest that the therapeutic performance (i.e., reduction in oxidative damage in tissues) of CUR can be enhanced by employing tocol acetate nanoemulsions (via improving pharmacokinetics and tissue distribution) as a platform for drug delivery in sepsis-induced organ injury.

No abstract

No abstract

No abstract

No abstract